Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Public ClinicalTrials.gov record NCT07110246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
Study identification
- NCT ID
- NCT07110246
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 96 participants
Conditions and interventions
Interventions
- Dabrafenib Drug
- Trametinib Drug
- Magnetic Resonance Imaging (MRI) Procedure
- Specimen Collection Procedure
- Optional Lumbar puncture Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 12 Months to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2025
- Primary completion
- Mar 30, 2032
- Completion
- Mar 30, 2032
- Last update posted
- Sep 2, 2026
2025 – 2032
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Riley Hospital for Children at Indiana University Health | Indianapolis | Indiana | 46202 | Recruiting |
| John Hopkins Medical Center | Baltimore | Maryland | 21287 | Recruiting |
| St. Louis Children's Hospital Washington University in St. Louis | St Louis | Missouri | 63110 | Recruiting |
| Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Recruiting |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Recruiting |
| University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07110246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07110246 live on ClinicalTrials.gov.